Trial Profile
The Effect of BMS-986195 on the Pharmacokinetics of a Combined Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 29 Jun 2022
Price :
$35
*
At a glance
- Drugs Branebrutinib (Primary) ; Ethinylestradiol/norethisterone
- Indications Rheumatoid arthritis
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
- 04 Jun 2022 Results assessing the DDI potential of branebrutinib when co-administered with potential concomitant medications in 3 single-sequence, cross-over clinical studies in healthy participants presented at the 23rd Annual Congress of the European League Against Rheumatism
- 15 Feb 2018 Status changed from active, no longer recruiting to completed.
- 16 Jan 2018 Planned End Date changed from 26 Dec 2017 to 31 Jan 2018.